Pre-Open Stock Movers 10/07: (LPCN) (UVE) (GPS) Higher; (CLVS) (MG) (OPK) Lower (more...)
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Today's Pre-Open Stock Hovers
Clovis Oncology (Nasdaq: CLVS) 21.6% LOWER; announced the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is currently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017.
Lipocine Inc (NASDAQ: LPCN) 13.7% HIGHER; H.C. Wainwright initiated coverage with a Buy rating and a price target of $25
Universal Insurance (NYSE: UVE) 12.5% HIGHER; bounces as Florida avoids direct Hurricane Matthew.hit.
Mistras Group, Inc. (NYSE: MG) 7.2% LOWER; reported Q1 EPS of $0.22, $0.02 better than the analyst estimate of $0.20. Revenue for the quarter came in at $168.4 billion, versus $179.9 billion reported last year. GUIDANCE: Mistras Group, Inc. sees FY2017 EPS of $0.88-$0.97, versus prior guidance of $0.99-$1.12. Mistras Group, Inc. sees FY2017 revenue of $690-705 million, versus prior guidance of $720-735 million.
Opko Health (NASDAQ: OPK) 6% LOWER; Jefferies notes Palmetto posted a final LCD for OPK's 4Kscore prostate cancer test that argued against Medicare coverage.
Gap (NYSE: GPS) 6% HIGHER; September 2016 comparable sales by approximately 3%, which was better than expected.
SolarEdge Technologies (NASDAQ: SEDG) 5.9% LOWER; Goldman Sachs downgraded from Neutral to Sell.
CIT Group Inc. (NYSE: CIT) 5.8% HIGHER; announced that it has entered into a definitive agreement to sell CIT Commercial Air, its commercial aircraft leasing business, to Avolon Holdings Limited (Avolon), the international aircraft leasing company and a wholly-owned subsidiary of Bohai Capital Holding Co. Ltd. The transaction is expected to close by the end of the first quarter of 2017, subject to regulatory approvals and customary closing conditions.
Sunrun (NASDAQ: RUN) 5.7% HIGHER; Goldman Sachs upgraded from Neutral to Buy.
Ruby Tuesday (NYSE: RT) 5.2% LOWER; reported Q1 EPS of ($0.11), versus ($0.03) reported last year. Revenue for the quarter came in at $256.7 million, versus $279.48 million reported last year.
SCYNEXIS (NASDAQ: SCYX) 4.8% HIGHER; WBB Securities upgraded from Buy to Strong Buy.
Dynavax Technologies (NASDAQ: DVAX) 4% HIGHER; Steven Cohen's Point72 Asset Management, L.P. disclosed a 5.9%, or 2,280,608 share, stake in the company.
Tyson (NYSE: TSN) 4% LOWER; Pivotal Research downgraded from Hold to Sell with a price target of $40.00 (prior $100.00).
Merrimack Pharmaceuticals (NASDAQ: MACK) 3.8% LOWER; JPMorgan downgraded from Overweight to Neutral with a price target of $7.00 (from $8.00).
ncyte Corporation (Nasdaq: INCY) 3.1% HIGHER; announced that updated data from the Phase I portion of the ECHO-202 trial evaluating the safety and efficacy of epacadostat, Incytes selective IDO1 enzyme inhibitor, in combination with pembrolizumab (Keytruda®)*, Mercks anti-PD-1 therapy, have been published as a poster at the European Society for Medical Oncology (ESMO) Annual Congress 2016 in Copenhagen, Denmark.
Honeywell (NYSE: HON) 3% LOWER; updates guidance.
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3% HIGHER; H.C. Wainwright initiated coverage with a Buy rating and a price target of $22.
GW Pharma (NASDAQ: GWPH) 3% HIGHER; Goldman Sachs initiated coverage with a Buy rating and a price target of $189
Helen of Troy (NASDAQ: HELE) 2.7% LOWER; reported Q2 EPS of $1.31, $0.17 better than the analyst estimate of $1.14. Revenue for the quarter came in at $368.2 million versus the consensus estimate of $143.88 million. Helen of Troy reaffirmed FY2016 EPS guidance. For fiscal year 2017, the Company now expects consolidated net sales revenue in the range of $1.550 to $1.590 billion, versus prior guidance of $1.570 to $1.620 billion.
AxoGen, Inc. (Nasdaq: AXGN) 1.7% LOWER; announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.
Synergy Pharma (NASDAQ: SGYP) 1.5% LOWER; filed to offer 3,126,795 shares for holders.
Ralph Lauren (NYSE: RL) 1.2% HIGHER; Goldman Sachs upgraded from Buy to CL Buy with a price target of $120
Yahoo! (NASDAQ: YHOO) 1% LOWER; Verizon Communications (NYSE: VZ) is looking for Yahoo! (NASDAQ: YHOO) to give them a $1 billion discount on the $4.8 billion purchase price amid the e-mail hacking scandal and other missteps that have come to light after the announced deal, the New York Post reported citing several sources.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 12/09: (SWC) (SGYP) (FNSR) Higher; (XTLY) (RH) (DLTH) Lower (more...)
- Pre-Open Stock Movers 12/06: (TXMD) (IL) (GPRO) Higher; (SB) (MIK) (CMG) Lower (more...)
- Sunshine Heart (SSH) Adds to Thursday's Big Gains
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesSAC Capital, JPMorgan, Goldman Sachs, Steven A. Cohen, Jefferies & Co, Pre-Open Losers, Pre-Open Winners, Point72 Asset, Pre Market Movers, PDUFA, H.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!